Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8703410 | 0.81 | ABCB1 (0.56) | ABCB1CYP2D6HTR2AADRB2ADRB1 | |
| SCHEMBL10805464 | 0.78 | CYP2D6 (0.74) | ABCB1CYP2D6HTR2AHTR1A | |
| SCHEMBL30001633 | 0.78 | CYP2D6 (0.74) | ABCB1CYP2D6HTR2AHTR1A | |
| SCHEMBL16727482 | 0.77 | ABCB1 (0.70) | ABCB1ADRB2ADRB1 | |
| SCHEMBL16727483 | 0.77 | ABCB1 (0.75) | ABCB1KDM4ELMNASMN1; SMN2ADRB2 | |
| SCHEMBL8702938 | 0.77 | CYP2D6 (0.65) | ABCB1CYP2D6HTR2ALMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL10806395 | 0.77 | CYP2D6 (0.72) | ABCB1CYP2D6HTR2AHTR1A | |
| SCHEMBL8703202 | 0.76 | CYP2D6 (0.58) | ABCB1CYP2D6HTR2ALMNAHTR1A | |
| SCHEMBL8706577 | 0.76 | CYP2D6 (0.64) | ABCB1CYP2D6HTR2AADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL8703573 | 0.76 | CYP2D6 (0.64) | ABCB1CYP2D6HTR2AADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | PRKDC, MAP2K2, TTK | ABCB1 3336/4885CYP2D6 4556/4885HTR2A 3965/4885 |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | ABCB1 3336/4885CYP2D6 4556/4885HTR2A 3965/4885 |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | ABCB1 3336/4885CYP2D6 4556/4885HTR2A 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.